Startup profile · funding coverage
Anaheim Bio funding, valuation and investors
Preclinical biotech developing ANA-1 candidate treatment for calcium pyrophosphate deposition disease (CPPD).
Verified company research · funding, investors and latest developments
Keep track of Anaheim Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
€40M · November 5, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Leiden, Netherlands
Investors in latest funding
Other: Droia Ventures , Frazier Life Sciences , RTW , Novartis Venture Fund , RV Invest , Thuja Capital
Overview
Leiden, Netherlands preclinical-stage biotech spun out of Alesta Therapeutics prior to BioMarin acquisition. €40M Series A announced November 5 2026 to develop investigational small molecule ANA-1 against CPPD-related disease. Clinical entry planned in 2027; not yet proven in patients.
Why Anaheim Bio is interesting
Nov 5 2026 €40M Series A follows a spinout from Alesta Therapeutics; aims to enter human clinical trials in 2027. No clinical efficacy or approval established.
Product & use cases
ANA-1 is a research-stage small molecule. Development steps include preclinical validation, process chemistry, toxicology/IND-enabling studies and regulator-approved patient trials before any use in clinical practice. It is not commercially available. CPPD causes crystal-induced joint inflammation; treatment goals must be tested clinically, and company plans are not proof of efficacy.
- Investigational future disease-modifying treatment for CPPD patients, contingent on clinical safety and efficacy and authorization.
Funding history (newest first)
Series A
2026-11-05 €40M- Droia Ventures (participant)
- Frazier Life Sciences (participant)
- RTW (participant)
- Novartis Venture Fund (participant)
- RV Invest (participant)
- Thuja Capital (participant)
Source: Read source · prnewswire.co.uk
Competitive landscape
Edge: Potential mechanism-focused approach to disease vs symptomatic treatment; remains an unproven preclinical hypothesis.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.